ArticleInvestigative ophthalmology & visual science2026
Myogenic Differentiation (MyoD) Gene Expression in Cornea and Role in Corneal Myofibroblast Dedifferentiation.
Article in Investigative ophthalmology & visual science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Myogenic differentiation (MyoD), a class II basic helix-loop-helix transcription factor, regulates multiple cell functions, including fibrosis in many organs, but remains unknown in the cornea. This study characterized the expression of MyoD in non-fibrotic and fibrotic rabbit and human donor corneas and investigated the effects of MyoD gene silencing on corneal myofibroblast dedifferentiation in vitro and fibrosis in vivo. Methods: New Zealand White rabbits, human donor corneas, human corneal stromal fibroblasts (CSFs), and human corneal myofibroblasts (CMFs) were used. MyoD shRNA or scrambled shRNA was delivered into CMFs via Lipofectamine 3000 and rabbit cornea via 2-kDa polyethylenimine conjugated to gold nanoparticles (PEI2-GNPs). Quantitative real-time polymerase chain reaction (qRT-PCR), immunofluorescence, and western blotting quantified the expression of profibrotic genes, intermediate filaments, fibroblast-specific protein 1 (FSP1), and proliferation marker Ki67 in CMF-/+ MyoD gene silencing. Results: MyoD expression was detected in human and rabbit corneal epithelium, stroma, and endothelium. MyoD levels were significantly greater in fibrotic human corneas (P < 0.001) and rabbit corneas (P < 0.0001) than corresponding non-fibrotic corneas. Also, CMFs had significantly greater MyoD levels than CSFs (P < 0.0001). MyoD shRNA-silenced CMFs acquired a characteristic fibroblast phenotype and showed reduced fibrotic genes, alpha smooth muscle actin (αSMA; P < 0.0001), fibronectin (FN; P = 0.0015), collagen type I (ColI; P = 0.0011), and collagen type IV (ColIV; P = 0.0053) mRNA levels compared to the scrambled shRNA-delivered CMFs. Further, immunofluorescence demonstrated increased vimentin (P < 0.001), FSP1 (P < 0.01), and Ki67 expression (P = 0.0349) and decreased desmin expression (P < 0.001) in MyoD shRNA-silenced CMFs than the scrambled shRNA-delivered CMFs. MyoD shRNA-delivered rabbit corneas had less scarring in vivo (P = 0.368). Conclusions: MyoD is expressed in cornea and could amend CMF dedifferentiation and fibrosis in an injured cornea. Additional studies are warranted to define the potential of MyoD in corneal fibrosis management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.